A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus

Journal of Infectious Diseases

Volumn 208, Issue 6, 2013, Pages 1008-1019

  Fournillier, Anne ^a   Frelin, Lars ^b   Jacquier, Emilie ^a   Ahlén, Gustaf ^b   Brass, Anette ^b   Gerossier, Estelle ^a   Holmström, Fredrik ^b   Broderick, Kate E ^c   Sardesai, Niranjan Y ^c   Bonnefoy, Jean Yves ^a   Inchauspé, Geneviève ^a   Sällberg, Matti ^b  

^a TRANSGENE S A   (France)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Inovio Pharmaceuticals Inc   (United States)

Author keywords

electroporation; HCV; prime boost; therapeutic vaccine

Indexed keywords

CHRONVAC C; DNA VACCINE; EPITOPE; GAMMA INTERFERON; HEPATITIS C VACCINE; INTERLEUKIN 12; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MVATG16643 VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE RESPONSE; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS C; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ELECTROPORATION; HCV; PRIME/BOOST; THERAPEUTIC VACCINE;

ANIMALS; ANTIBODY FORMATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; INTERLEUKIN-2; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION; VACCINES, DNA; VIRAL HEPATITIS VACCINES;

EID: 84883224523     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit267     Document Type: Conference Paper

References (44)

1. Thimme R, Oldach D, Chang KM, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194:1395-406.
2. Shoukry NH, Grakoui A, Houghton M, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197:1645-55.
3. Lauer GM, Barnes E, Lucas M, et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 2004; 127:924-36.
4. Cox AL, Mosbruger T, Lauer GM, et al. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology 2005; 42:104-12.
5. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005; 436:946-52.
6. Grakoui A, ShoukryNH,WoollardDJ, et al.HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302:659-62.
7. Wedemeyer H, He XS, Nascimbeni M, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002; 169:3447-58.
8. Gruener NH, Lechner F, Jung MC, et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 2001; 75:5550-8.
9. Söderholm J, Sällberg M. A complete mutational fitness map of the hepatitis C virus nonstructural 3 protease: relation to recognition by cytotoxic T lymphocytes. J Infect Dis 2006; 194:1724-8.
10. Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437:1167-72.
11. Radziewicz H, Hanson HL, Ahmed R, et al. Unraveling the role of PD-1/PD-L interactions in persistent hepatotropic infections: potential for therapeutic application? Gastroenterology 2008; 134:2168-71.
12. Urbani S, Amadei B, Tola D, et al. Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. J Hepatol 2008; 48:548-58.
13. Klade CS, Wedemeyer H, Berg T, et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008; 134:1385-95.
14. Eisenstein M. Vaccines: a moving target. Nature 2011; 474:S16-7.
15. Fournillier A, Gerossier E, Evlashev A, et al. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Vaccine 2007; 25:7339-53.
16. Habersetzer F, Honnet G, Bain C, et al. A poxvirus vaccine is safe, induces t-cell responses, and decreases viral load in patients with chronic hepatitis c. Gastroenterology 2011; 141:890-9.
17. Wedemeyer H. Hepatology 2011; 54(Suppl. 4):989A-90A.
18. Ahlén G, Söderholm J, Tjelle T, et al. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol 2007; 179:4741-53.
19. Weiland O, Ahlén G, Diepolder H, Jung MC, Levander S, Fons M, Mathiesen I, Sardesai NY, Vahlne A, Frelin L. Sällberg M.Therapeutic DNAVaccination Using In Vivo Electroporation Followed by Standard of Care Therapy in Patients With Genotype 1 Chronic Hepatitis C. Mol Ther. 2013; doi: 10.1038/mt.2013.119.
20. Winstone N, Guimaraes-Walker A, Roberts J, et al. Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNAmodified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay. Eur J Immunol 2009; 39:975-85.
21. Dunachie SJ,Walther M, Epstein JE, et al. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 2006; 74:5933-42.
22. McConkey SJ, Reece WH, Moorthy VS, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003; 9:729-35.
23. Lang Kuhs KA, Ginsberg AA, Yan J, et al. Hepatitis C virus NS3/NS4A DNAvaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses. Mol Ther 2012; 20:669-78.
24. Hutnick NA, Myles DJ, Hirao L, et al. An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge. Vaccine 2012; 30:3202-8.
25. Pascolo S, Bervas N, Ure JM, et al. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2 m) HLA-A2.1 monochain transgenic H-2Db beta2 m double knockout mice. J Exp Med 1997; 185:2043-51.
26. Frelin L, Ahlen G, Alheim M, et al. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene. Gene Ther 2004; 11:522-33.
27. Kato N, Hijikata M, Ootsuyama Y, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990; 87:9524-8.
28. Sällberg M, Ruden U,Magnius LO, et al. Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol Lett 1991; 30:59-68.
29. Chen A, Ahlén G, Brass A, et al. Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3/4A-specific T cells during therapeutic vaccination. J Immunol 2011; 186:5107-18.
30. Simon BE, Cornell KA, Clark TR, et al. DNA vaccination protects mice against challenge with Listeria monocytogenes expressing the hepatitis C virus NS3 protein. Infect Immun 2003; 71:6372-80.
31. Nyström J, Chen A, Frelin L, et al. Improving on the ability of endogenous hepatitis B core antigen to prime cytotoxic T lymphocytes. J Infect Dis 2010; 201:1867-79.
32. Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol 2011; 54:1273-85.
33. Halliday J, Klenerman P, Barnes E. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines 2011; 10:659-72.
34. Estcourt MJ, Ramsay AJ, Brooks A, et al. Prime-boost immunization generates a high frequency, high-avidity CD8+ cytotoxic T lymphocyte population. Int Immunol 2002; 14:31-7.
35. Woodland DL. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004; 25:98-104.
36. Pancholi P, Perkus M, Tricoche N, et al. DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. J Virol 2003; 77:382-90.
37. Folgori A, Capone S, Ruggeri L, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006; 12:190-7.
38. Lin Y, Kwon T, Polo J, et al. Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J Virol 2008; 82:7492-503.
39. Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012; 4:115ra1.
40. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8: 247-58.
41. Cellerai C, Harari A, Stauss H, et al. Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors. PLoS One 2011; 6:e18164.
42. Badr G, Bedard N, Abdel-Hakeem MS, et al. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol 2008; 82:10017-31.
43. Kastenmuller W, Drexler I, Ludwig H, et al. Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity. Virology 2006; 350:276-88.
44. Gasteiger G, Kastenmuller W, Ljapoci R, et al. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J Virol 2007; 81:11925-36.